Aberdeen Wealth Management LLC Has $687,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Aberdeen Wealth Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 9.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 776 shares of the company’s stock after selling 79 shares during the period. Aberdeen Wealth Management LLC’s holdings in Eli Lilly and Company were worth $687,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of LLY. Vaughan David Investments LLC IL increased its position in shares of Eli Lilly and Company by 6.7% during the first quarter. Vaughan David Investments LLC IL now owns 3,821 shares of the company’s stock worth $2,973,000 after acquiring an additional 239 shares in the last quarter. Ossiam increased its holdings in Eli Lilly and Company by 28.4% during the 1st quarter. Ossiam now owns 90,675 shares of the company’s stock worth $70,542,000 after purchasing an additional 20,046 shares in the last quarter. Elgethun Capital Management raised its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. Elgethun Capital Management now owns 23,541 shares of the company’s stock valued at $17,850,000 after purchasing an additional 11,620 shares during the period. Crewe Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $1,191,000. Finally, Payden & Rygel Investment Group acquired a new position in shares of Eli Lilly and Company during the first quarter worth about $20,631,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.5 %

Shares of Eli Lilly and Company stock opened at $727.57 on Tuesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The business has a fifty day simple moving average of $879.04 and a two-hundred day simple moving average of $870.84. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a market capitalization of $690.70 billion, a price-to-earnings ratio of 78.66, a P/E/G ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. Research analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.71%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on LLY. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, BMO Capital Markets raised their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.